U.S. FDA places partial hold on AstraZeneca cancer drug trials
LONDON, Oct (HKSE: 3366-OL.HK - news) 27 (Reuters) - U.S. health authorities have placed a partial clinical hold on the enrolment of new patients with head and neck cancer into studies involving AstraZeneca (NYSE: AZN - news) 's big new drug hope durvalumab, the company said on Thursday.
The drugmaker said the Food and Drug Administration action related only to head and neck cancer, adding that trials were continuing with existing patients. Trials of the immunotherapy drug in different cancer types are also progressing as planned. (Reporting by Ben Hirschler; Editing by Martinne Geller)